Register
No increased risk of major adverse cardiac events found with lorcaserin |
Journal Updates
eMediNexus Coverage from: 
No increased risk of major adverse cardiac events found with lorcaserin
eMediNexus,  24 July 2018
remove_red_eye 778 Views
#Cardiology #Internal Medicine #Pharmacist

0 Read Comments                

Results from a 12,000 patient post-marketing safety study mandated by the US Food and Drug Administration (FDA) show that lorcaserin, the obesity drug does not increase the risk of any major adverse cardiac events (MACE), which included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!